Headlines about Thermo Fisher Scientific (NYSE:TMO) have trended somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Thermo Fisher Scientific earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned headlines about the medical research company an impact score of 45.8416691177493 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news headlines that may have effected Accern’s scoring:
- Trading summary of Unusual Activity – Thermo Fisher Scientific Inc … – Wall Street Morning (wallstreetmorning.com)
- Thermo Fisher Scientific Inc. (TMO) CFO Stephen Williamson Sells 5,000 Shares (americanbankingnews.com)
- Is Thermo Fisher Scientific Inc’s (NYSE:TMO) Balance Sheet A Threat To Its Future? (finance.yahoo.com)
- Insider Selling: Thermo Fisher Scientific Inc. (TMO) Insider Sells 6,000 Shares of Stock (americanbankingnews.com)
- Gregory J. Herrema Sells 33,327 Shares of Thermo Fisher Scientific Inc. (TMO) Stock (americanbankingnews.com)
Several research analysts recently issued reports on TMO shares. Morgan Stanley increased their price objective on Thermo Fisher Scientific from $223.00 to $227.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Barclays increased their price objective on Thermo Fisher Scientific from $225.00 to $245.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Leerink Swann restated an “outperform” rating and set a $239.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Thursday, February 1st. They noted that the move was a valuation call. ValuEngine upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Friday, February 2nd. Finally, Bank of America upped their target price on Thermo Fisher Scientific from $235.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, February 1st. Two investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $220.50.
Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, January 31st. The medical research company reported $2.79 earnings per share for the quarter, topping the consensus estimate of $2.66 by $0.13. Thermo Fisher Scientific had a return on equity of 16.01% and a net margin of 10.64%. The company had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $5.72 billion. During the same period last year, the firm earned $2.41 EPS. The firm’s revenue for the quarter was up 22.1% compared to the same quarter last year. equities analysts anticipate that Thermo Fisher Scientific will post 10.81 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Monday, April 16th. Investors of record on Thursday, March 15th will be paid a $0.17 dividend. The ex-dividend date is Wednesday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. This represents a $0.68 dividend on an annualized basis and a yield of 0.34%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.71%.
In related news, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total value of $9,419,500.00. Following the transaction, the chief executive officer now directly owns 252,577 shares of the company’s stock, valued at approximately $47,582,981.03. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Gregory J. Herrema sold 33,327 shares of the firm’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $219.70, for a total transaction of $7,321,941.90. Following the completion of the transaction, the senior vice president now directly owns 60,471 shares in the company, valued at $13,285,478.70. The disclosure for this sale can be found here. Insiders sold a total of 144,327 shares of company stock worth $28,680,042 over the last ninety days. 0.49% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Thermo Fisher Scientific (NYSE:TMO) Receives Daily News Impact Score of 0.11” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://stocknewstimes.com/2018/02/11/thermo-fisher-scientific-tmo-earns-media-sentiment-score-of-0-11.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.